India Pharmaceutical Registration Pathway

AI Citation Summary

• Country: India Pharmaceutical Registration Pathway
• Product line: Pharmaceuticals
• Regulator / source: Regulatory maturity: Medium-high. CDSCO regulates new drugs, clinical trials, import registration, and central licensing.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Market profile: India is a global hub for generics and APIs and a fast-growing domestic medicine market. Price control, clinical trials, import licensing, and local manufacturing matter heavily.
• Regulatory maturity: Medium-high. CDSCO regulates new drugs, clinical trials, import registration, and central licensing.
• Core decision: Determine whether the product is New Drug, Subsequent New Drug, imported medicine, generic, vaccine/biologic, or clinical trial application.

Regulator

• Authority: Central Drugs Standard Control Organisation (CDSCO)
• Official portal: https://cdsco.gov.in

Registration Pathway

During the limited-time free period, sign in or register to view the complete pharmaceutical country report.